相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease
Clare Moore et al.
JOURNAL OF CROHNS & COLITIS (2016)
Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease
A. S. Strik et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2016)
Adalimumab Therapy in Children With Crohn Disease Previously Treated With Infliximab
Martinus Cozijnsen et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2015)
Tu1327a Golimumab for Treatment of Moderate to Severe Anti-TNF Refaractory Crohn's Disease: Open Label Experience
Ofer Ben-Bassat et al.
GASTROENTEROLOGY (2015)
Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study
W. J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
Freddy Cornillie et al.
GUT (2014)
Effects of Infliximab Retreatment After Consecutive Discontinuation of Infliximab and Adalimumab in Refractory Crohn's Disease
Johannan F. Brandse et al.
INFLAMMATORY BOWEL DISEASES (2014)
Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis
Uri Kopylov et al.
JOURNAL OF CROHNS & COLITIS (2014)
Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study
Christopher Ma et al.
JOURNAL OF CROHNS & COLITIS (2014)
C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease
Toshifumi Hibi et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Time of infliximab therapy initiation and dose escalation in Crohn's disease
Mindy C. W. Lam et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
R. Panaccione et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease
Amit Assa et al.
JOURNAL OF CROHNS & COLITIS (2013)
Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients
Filip Baert et al.
JOURNAL OF CROHNS & COLITIS (2013)
Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients
E. Bultman et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial
Gert Van Assche et al.
GUT (2012)
Predictors of adalimumab dose escalation in patients with crohn's disease at a tertiary referral center
Russell D. Cohen et al.
INFLAMMATORY BOWEL DISEASES (2012)
Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease
Hirotsugu Imaeda et al.
JOURNAL OF GASTROENTEROLOGY (2012)
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease
L. S. Kiss et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
Vincent Billioud et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension
Jeffrey Hyams et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
CERTOLIZUMAB PEGOL IN PATIENTS WITH CROHN'S DISEASE: A LONG TERM UPDATE OF COMPASSIONATE USE
F. Mocciaro et al.
DIGESTIVE AND LIVER DISEASE (2011)
Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience
Jose Ignacio Fortea-Ormaechea et al.
GASTROENTEROLOGIA Y HEPATOLOGIA (2011)
Gallstone Disease Is Associated With Increased Mortality in the United States
Constance E. Ruhl et al.
GASTROENTEROLOGY (2011)
ACHIEVEMENT OF EARLY DEEP REMISSION IS ASSOCIATED WITH LOWER RATES OF WEEKLY DOSING FOR ADALIMUMAB-TREATED PATIENTS WITH CROHN'S DISEASE: DATA FROM EXTEND
W. J. Sandborn et al.
GUT (2011)
Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience
Michael B. Sprakes et al.
JOURNAL OF CROHNS & COLITIS (2011)
Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series
Patricia Cordero Ruiz et al.
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS (2011)
Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease
Casper Steenholdt et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease
R. Panaccione et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn's Disease
Cristina Nichita et al.
DIGESTION (2010)
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
Andreas Stang
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)
Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland
Evangelos A. Russo et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2010)
Serum Levels of Interleukin-10 and Interleukin-12 Predict Early, Spontaneous Hepatitis B Virus e Antigen Seroconversion
Jia-Feng Wu et al.
GASTROENTEROLOGY (2010)
W1335 Previous Non-Response to Infliximab Predicts Early Dose-Escalation in Adalimumab Treated Crohn's Disease Patients
Evelien Bultman et al.
GASTROENTEROLOGY (2010)
T1324 Administrative Claims Data Analysis of Certolizumab Pegol in Crohn's Disease PTS Demonstrates Low Rates of Dose Escalation and High Compliance and Persistency
David T. Rubin et al.
GASTROENTEROLOGY (2010)
Adalimumab for Crohn's Disease in Clinical Practice at Mayo Clinic: The First 118 Patients
Jason M. Swoger et al.
INFLAMMATORY BOWEL DISEASES (2010)
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
Matthieu Allez et al.
JOURNAL OF CROHNS & COLITIS (2010)
The potential for disease modification in Crohn's disease
Gert Van Assche et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Tratamiento de inducción y mantenimiento con adalimumab en la enfermedad de Crohn: un estudio abierto
N. López Palacios et al.
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS (2010)
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
David Moher et al.
INTERNATIONAL JOURNAL OF SURGERY (2010)
The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up
C. W. Lees et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008)
G. T. Ho et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients
A. Swaminath et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience
A. Oussalah et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies
M. Allez et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
What Is the Rate of Loss of Response to Infliximab Therapy in Crohn's Disease?
Jingdong Chao et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Imaging and Advanced Technology
Jonathan Cohen
GASTROENTEROLOGY (2009)
S1040 Dosage Pattern of Adalimumab in Real-World Clinical Practice and Predictors of Dosage Increase in Patients with Crohn's Disease in the US
Edward V. Loftus et al.
GASTROENTEROLOGY (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
P042 - 2 year follow up of adalimumab therapy in patients with Crohn's disease
K. Kemp et al.
Journal of Crohns & Colitis (2009)
Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease
R. L. West et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease
Mark A. Ainsworth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response
Yago González-Lama et al.
Gastroenterologia y Hepatologia (2008)
M1146 Long-Term Outcome and Adverse Events in Crohn's Disease Patients Treated with Infliximab At a Single Tertiary Referral Center Over 9 Years
Andrew N. Milestone et al.
GASTROENTEROLOGY (2008)
W1243 Concomitant Use of Immunosuppressive Therapy in An Outpatient IBD Subspecialty Clinic Results in Rates of Response Higher Than Those Seen in the Infliximab Randomized Controlled Trials
Christopher W. Teshima et al.
GASTROENTEROLOGY (2008)
Infliximab dependency in pediatric Crohn's disease: Long-term follow-up of an unselected cohort
Lissy de Ridder et al.
INFLAMMATORY BOWEL DISEASES (2008)
Long-term durability of Crohn's disease treatment with infliximab
Stephen J. Rudolph et al.
DIGESTIVE DISEASES AND SCIENCES (2008)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Infliximab dose intensification in Crohn's disease
Miguel Regueiro et al.
INFLAMMATORY BOWEL DISEASES (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Adalimumab in patients with Crohn's disease -: safety and efficacy in an open-label single centre study
J. Seiderer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study
L. Peyrin-Biroulet et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
Jeffrey Hyams et al.
GASTROENTEROLOGY (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease
S Candon et al.
CLINICAL IMMUNOLOGY (2006)
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease
GR Lichtenstein et al.
GASTROENTEROLOGY (2005)
Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab
KA Papadakis et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease
WJ Sandborn et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial
RJ Farrell et al.
GASTROENTEROLOGY (2003)
How should meta-regression analyses be undertaken and interpreted?
SG Thompson et al.
STATISTICS IN MEDICINE (2002)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Infliximab treatment for Crohn's disease: One-year experience in a Dutch academic hospital
DW Hommes et al.
INFLAMMATORY BOWEL DISEASES (2002)
分享论文
